非小细胞肺癌中非耐药罕见EGFR突变的模式、EGFR-TKI疗效及预后因素
这项多中心回顾性研究纳入177例携带非耐药罕见EGFR突变(非L858R、19外显子缺失、20外显子插入及T790M)的NSCLC患者,占1983例的8.9%。初治晚期患者中,阿法替尼组客观缓解率60.6%高于吉非替尼/厄洛替尼组35.8%(p=0.036),但中位PFS和OS无显著差异。诊断时脑转移与更短PFS和OS相关。
要点
- 初治晚期患者阿法替尼ORR 60.6%优于吉非替尼/厄洛替尼35.8%(p=0.036)。
- 两药中位PFS和OS无显著差异,诊断时脑转移预后差。
核心结论
- 对携带非耐药罕见EGFR突变的NSCLC,一线阿法替尼可能较吉非替尼/厄洛替尼提高治疗反应但无生存获益。
- 诊断时脑转移与更短PFS和OS相关。
研究设计与样本
- 多中心回顾性研究,纳入177例携带非耐药罕见EGFR突变的NSCLC患者(177/1983,8.9%)。
- 非耐药罕见EGFR突变定义为除L858R、19外显子缺失、20外显子插入和T790M以外的突变。
- 按一线EGFR-TKI分为吉非替尼/厄洛替尼组和阿法替尼组。
主要发现
- 初治晚期患者(n=72)中,吉非替尼/厄洛替尼组客观缓解率35.8%,阿法替尼组60.6%(p=0.036)。
- 多因素分析显示吉非替尼/厄洛替尼组与阿法替尼组的中位PFS和OS无显著差异。
- 诊断时脑转移与更短PFS相关(HR=2.49,95%CI=1.29-4.83)和更短OS相关(HR=3.22,95%CI=1.41-7.35)。
临床怎么用
- 对非耐药罕见EGFR突变晚期NSCLC初治患者,可考虑阿法替尼以提高客观缓解率。
- 诊断时脑转移提示预后不良,需加强监测和综合管理。
局限性
- 回顾性研究设计。
- 样本量有限(共177例,初治晚期72例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or L858R mutation usually respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), whereas T790M mutation and exon 20 insertion are frequently resistant to EGFR-TKIs. EGFR mutations other than those above are seldom investigated. METHODS: In this multicentre, retrospective study, we enrolled NSCLC patients with non-resistant uncommon EGFR mutations, which were defined as mutations other than L858R, exon 19 deletions, exon 20 insertions and T790M. The mutation patterns, clinical data and treatment outcomes were analysed. Patients were classified as gefitinib/erlotinib and afatinib groups according to the EGFR-TKIs received as the first-line therapy. RESULTS: A total of 177 patients were identified (177/1983, 8.9%). Sixty-six patients had more than one EGFR mutation, including those coexisting with exon 19 deletion or L858R mutation. In treatment-naïve patients with advanced stages (n = 72), the objective response rate was 35.8% for gefitinib/erlotinib group and 60.6% for afatinib group (p = 0.036). In multivariate analysis, no significant differences were found between gefitinib/erlotinib and afatinib groups in median progression-free survival (PFS) and overall survival (OS). Brain metastasis at diagnosis was associated with a shorter PFS (hazard ratio [HR] = 2.49, 95% confidence interval [CI] = 1.29-4.83) and OS (HR = 3.22, 95% CI = 1.41-7.35). CONCLUSIONS: For patients with NSCLC harbouring non-resistant uncommon EGFR mutations, afatinib use as the first-line therapy may provide a better treatment response but no survival benefit, as compared with gefitinib or erlotinib. Brain metastasis at diagnosis is associated with a poor prognosis.
引用
- Chang LC, Lim CK, Chang LY, et al. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. Eur J Cancer. 2019. PMID: 31425965. doi:10.1016/j.ejca.2019.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。